1
|
George J, Wilkins S, Critch N, Gunawan L, Cortes M, Liu X, Laughton K, Nurjono M, Volitakis I, Huggins P, Parsons J, McNaughton M, Adlard P, Masters C, Cappai R, Barnham K, Gautier E, Bush A, Cherny R, Finkelstein D. P1.050 Novel neuroprotective agents for the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70172-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Caragounis A, Du T, Filiz G, Laughton K, Volitakis I, Sharples R, Cherny R, Masters C, Drew S, Hill A, Li QX, Crouch P, Barnham K, White A. Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. Biochem J 2007; 407:435-50. [PMID: 17680773 PMCID: PMC2275059 DOI: 10.1042/bj20070579] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Biometals have an important role in AD (Alzheimer's disease) and metal ligands have been investigated as potential therapeutic agents for treatment of AD. In recent studies the 8HQ (8-hydroxyquinoline) derivative CQ (clioquinol) has shown promising results in animal models and small clinical trials; however, the actual mode of action in vivo is still being investigated. We previously reported that CQ-metal complexes up-regulated MMP (matrix metalloprotease) activity in vitro by activating PI3K (phosphoinositide 3-kinase) and JNK (c-jun N-terminal kinase), and that the increased MMP activity resulted in enhanced degradation of secreted Abeta (amyloid beta) peptide. In the present study, we have further investigated the biochemical mechanisms by which metal ligands affect Abeta metabolism. To achieve this, we measured the effects of diverse metal ligands on cellular metal uptake and secreted Abeta levels in cell culture. We report that different classes of metal ligands including 8HQ and phenanthroline derivatives and the sulfur compound PDTC (pyrrolidine dithiocarbamate) elevated cellular metal levels (copper and zinc), and resulted in substantial loss of secreted Abeta. Generally, the ability to inhibit Abeta levels correlated with a higher lipid solubility of the ligands and their capacity to increase metal uptake. However, we also identified several ligands that potently inhibited Abeta levels while only inducing minimal change to cellular metal levels. Metal ligands that inhibited Abeta levels [e.g. CQ, 8HQ, NC (neocuproine), 1,10-phenanthroline and PDTC] induced metal-dependent activation of PI3K and JNK, resulting in JNK-mediated up-regulation of metalloprotease activity and subsequent loss of secreted Abeta. The findings in the present study show that diverse metal ligands with high lipid solubility can elevate cellular metal levels resulting in metalloprotease-dependent inhibition of Abeta. Given that a structurally diverse array of ligands was assessed, the results are consistent with the effects being due to metal transport rather than the chelating ligand interacting directly with a receptor.
Collapse
Affiliation(s)
- Aphrodite Caragounis
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
| | - Tai Du
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
| | - Gulay Filiz
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
| | - Katrina M. Laughton
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
| | - Irene Volitakis
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
| | - Robyn A. Sharples
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- §Bio21 Molecular Science and Biotechnology Institute, Parkville, Victoria 3052, Australia
- ∥Department of Biochemistry and Molecular Biology, The University of Melbourne, Victoria 3010, Australia
| | - Robert A. Cherny
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
| | - Colin L. Masters
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
| | - Simon C. Drew
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- §Bio21 Molecular Science and Biotechnology Institute, Parkville, Victoria 3052, Australia
| | - Andrew F. Hill
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- §Bio21 Molecular Science and Biotechnology Institute, Parkville, Victoria 3052, Australia
- ∥Department of Biochemistry and Molecular Biology, The University of Melbourne, Victoria 3010, Australia
| | - Qiao-Xin Li
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
| | - Peter J. Crouch
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
| | - Kevin J. Barnham
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- §Bio21 Molecular Science and Biotechnology Institute, Parkville, Victoria 3052, Australia
| | - Anthony R. White
- *Department of Pathology, The University of Melbourne, Victoria 3010, Australia
- †The Mental Health Research Institute, Parkville, Victoria 3052, Australia
- ‡Centre for Neuroscience, The University of Melbourne, Victoria 3010, Australia
- To whom correspondence should be addressed (email )
| |
Collapse
|
4
|
Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, Armour KL, Rood J, Kypridis A, Kronina V, Murphy R, Lee FT, Liu Z, Kitamura K, Ritter G, Laughton K, Hoffman E, Burgess AW, Old LJ. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000; 60:3254-61. [PMID: 10866319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The Lewis Y (Ley) antigen is a blood group-related antigen that is expressed in a high proportion of epithelial cancers (including breast, colon, ovary, and lung cancer) and is an attractive target for monoclonal antibody-directed therapy. The murine monoclonal 3S193 (IgG3) was generated in BALB/c mice by immunization with Ley-expressing cells of the MCF-7 breast carcinoma cell-line. The murine 3S193 showed high specificity for Ley in ELISA tests with synthetic Ley and Ley-containing glycoproteins and glycolipids and also reacted strongly in rosetting assays and cytotoxic tests with Ley-expressing cells. We generated a humanized form of the murine 3S193 antibody by linking cDNA sequences encoding the variable region of murine 3S913 with frameworks of the human KOL heavy chain and REI K chain. The genes for the humanized 3S193 monoclonal antibody IgG1 were transfected into mouse myeloma NS0 cells and cloned for the establishment of high antibody-producing colonies. Humanized 3S193 antibody was subsequently produced through in vitro culture and under good manufacturing practice conditions using hollow-fiber bioreactors. The purified humanized 3S193 (hu3S193) was subsequently characterized and validated for use in preliminary immunotherapy investigations. hu3S193 reacted specifically with Ley antigen, with similar avidity to the murine form. hu3S193 demonstrated potent immune effector function, with higher antibody-dependent cell-mediated cytotoxicity than its murine counterpart and potent complement-dependent cytotoxicity (ED50, 1.0 microg/ml). The in vivo immunotherapeutic potential of hu3S193 was assessed in a human breast xenograft model using MCF-7, Ley-positive cells. Six i.v. doses of up to 1 mg of hu3S193 were administered to animals bearing established tumors (120-130 mm3) with no significant effect on tumor growth. In contrast, in an MCF-7 xenograft preventive model, a 1-mg hu3S193 dosage schedule was able to significantly slow tumor growth compared with placebo and isotype-matched control IgG1 antibody. hu3S193 has promise for immunotherapy of Ley-positive tumors and is currently entering Phase I clinical trials.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal/therapeutic use
- Biosensing Techniques
- Breast Neoplasms/therapy
- Cloning, Molecular
- DNA, Complementary/metabolism
- Dose-Response Relationship, Immunologic
- Enzyme-Linked Immunosorbent Assay
- Humans
- Hybridomas/immunology
- Kinetics
- Lewis Blood Group Antigens/immunology
- Mammary Neoplasms, Experimental/therapy
- Mice
- Mice, Inbred BALB C
- Molecular Sequence Data
- Neoplasm Transplantation
- Neoplasms/therapy
- Sequence Homology, Amino Acid
- Time Factors
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- A M Scott
- Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Victoria, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|